FDA reg review targets three-quarters of rules for deletion or modification.
This article was originally published in The Gray Sheet
Executive SummaryFDA REG REVIEW TARGETS THREE-QUARTERS OF AGENCY RULES for deletion or "reinvention," FDA Office of External Affairs Deputy Commissioner Sharon Smith Holston said June 21 at the National Association of Pharmaceutical Manufacturers mid-year meeting in Washington, D.C. Over the past year, FDA has conducted a line-by-line review of its regulations and found that over 1,300 pages could be deleted or modified. The review excluded rules concerning product approvals and classifications.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.